News | March 03, 2022
Merck KGaA reports higher profits on strong volumes across its businesses
Company expects strong organic growth in sales, EBITDA in 2022
Company expects strong organic growth in sales, EBITDA in 2022
This innovative biomanufacturing technology will help to deliver cost-effective viral production that is unmatched in the industry
Adds to Merck’s growing global, multi-modality CDMO network, following newly formed CDMO business unit in Life Science
More than 2,500 submissions are currently under review in the Food and Drug Administration's (FDA) cell and gene therapy pipeline
Newly formed Life Science Services business unit to offer fully integrated CDMO and Contract Testing Services
It will enable the company to branch out to new geographies and strengthen its presence in South Africa
The transaction is expected to close in the first quarter of 2022
He has over 22 years of experience in pharmaceutical sales & business development
The investment in Yapan Bio allows Piramal Pharma Solutions to broaden its service offerings in the fast-growing biologics CDMO space
It’s the company’s fourth manufacturing site worldwide. Others are located in the US, UK and China
Subscribe To Our Newsletter & Stay Updated
